Tufts Center director stresses need for greater utilization of e-technologies to improve quality of clinical trials

Kaitin told the audience that invalid data in clinical trials, as well as the cost and volume of paper-based data collection have contributed to the rapid rise in the cost of drug development.

By Editor on May 22, 2003

Kaitin told the audience that invalid data in clinical trials, as well as the cost and volume of paper-based data collection have contributed to the rapid rise in the cost of drug development. Kaitin presented data supporting the need for dramatic improvement in clinical trial efficiency.

"Business as usual is no longer an option for drug developers struggling with rapidly rising R&D costs, long clinical development times, and high levels of risk," said Kaitin. "Successful firms will be those that integrate new e-technologies to improve the efficiency and quality of clinical trials."

The presentation was part of a seminar entitled, "Practical Strategies for Improving R&D Efficiency," sponsored by PHT Corporation, in conjunction with Palm, ClinPhone Group, and Perceptive Informatics.